• Revenue from continuing operations up 15.5% to $4.0 million
• EBITDA from continuing operations increased 214.16% to $0.24 million
• Net loss after tax from continuing operations reduced by 89.8% to $0.07 million

Careteq Limited has reported its financial results for the half-year ended 31 December 2024. The company's revenue from continuing operations increased by 15.5% to $4.0 million, while EBITDA from continuing operations improved by 214.16% to $0.24 million. The net loss after tax from continuing operations was reduced by 89.8% to $0.07 million. These results were driven by the company's streamlined focus on medication management, the successful integration of Embedded Health Solutions (EHS), and the expansion of the HMR Referrals platform. Careteq also formed strategic partnerships with MedicAlert and GP networks, which are expected to drive further growth. The divestment of the Sofihub business and the acquisition of the remaining 45% stake in EHS have strengthened the company's operations and financial position. Careteq expects to deliver full-year revenue growth in FY25 and a positive group EBITDA from continuing operations for the full year.

Careteq expects full year revenue growth in FY25 over the prior corresponding period and a positive group EBITDA from continuing operations result for the full year.

Careteq's first half performance was extremely pleasing, delivering a vastly improved financial performance. The company expects to continue this positive momentum and deliver further growth and profitability in the coming periods.